Adaptive Phage Therapeutics Funding & Investors
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to beco... Read more
aphage.comTotal Amount Raised: $123,925,000
Adaptive Phage Therapeutics Funding Rounds
Series B
$12,000,000
Series B Investors
AMR Action FundDeerfield Capital ManagementGrant
$5,000,000
Grant Investors
Defense Health AgencySeries B
$20,000,000
Series B Investors
AMR Action FundSeries B
$40,750,000
Series B Investors
Deerfield ManagementMayo ClinicConvertible Note
$6,175,000
Convertible Note Investors
Mayo ClinicGrant
$33,000,000
Grant Investors
Oxford Construction of PennsylvaniaSeries Unknown
$7,000,000
Series Unknown Investors
Alexandria Venture Investments
Funding info provided by Diffbot.